+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Companion Diagnostics Market - Global Forecast 2026-2032- Product Image
Companion Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Companion Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5336915
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Companion Diagnostics Market is projected to reach USD 9.84 Billion in 2026. It is expected to continue growing at a CAGR of 10.99%, reaching USD 18.48 Billion by 2032.

Companion diagnostics (CDx) have become a central operating model for precision medicine, linking a validated diagnostic test to the safe and effective use of a specific therapy. In oncology, rare disease, infectious disease, and immunology, CDx enables clinicians to identify patients most likely to benefit from targeted treatment, avoid ineffective therapies, and support evidence-based reimbursement decisions.

Momentum is reinforced by the rising global cancer burden, broader adoption of next-generation sequencing (NGS), increasing regulatory approvals for biomarker-linked targeted therapies, and expanding clinical use of biomarkers such as EGFR, ALK, BRAF, HER2, BRCA1/2, PD-L1, MSI, NTRK, and KRAS. As drug development becomes more biomarker-led, pharmaceutical sponsors, diagnostic developers, laboratories, and health systems are aligning around integrated clinical validation, regulatory strategy, guideline adoption, and real-world evidence generation.

Transformative Shifts in the Companion Diagnostics Landscape

The companion diagnostics landscape is shifting from single-analyte testing toward multiplex and NGS-based platforms that can evaluate multiple actionable biomarkers from limited tissue or blood samples. This shift supports faster treatment selection, better use of biopsy material, and stronger alignment with modern oncology pathways where several targeted therapy options may be available for one tumor type.

Regulatory and reimbursement expectations are also transforming the sector. Agencies including the U.S. FDA require strong analytical and clinical validation for CDx claims, while payers increasingly assess clinical utility, guideline inclusion, and health-economic value. Liquid biopsy, decentralized testing networks, tumor-agnostic biomarkers, and standardized laboratory quality systems are further changing how precision medicine is delivered across community and academic care settings.

Cumulative Impact of Artificial Intelligence on Companion Diagnostics

Artificial intelligence is influencing companion diagnostics by improving variant interpretation, digital pathology workflows, radiomics, laboratory automation, quality control, and clinical trial matching. AI-enabled tools can help prioritize genomic alterations, detect patterns in pathology images, support biomarker discovery, and synthesize evidence from real-world datasets when appropriately validated.

The cumulative impact of AI is expected to be strongest where it reduces turnaround time, improves reproducibility, and connects multi-omic data with therapy selection. However, adoption depends on transparent validation, representative training datasets, cybersecurity, explainability, clinical workflow integration, and compliance with medical device regulations, HIPAA, GDPR, and emerging AI governance frameworks such as the European Union AI Act.

Key Regional Insights for Companion Diagnostics

North America remains a leading region for companion diagnostics due to strong FDA regulatory pathways, a high concentration of biopharmaceutical innovation, broad molecular testing infrastructure, and rapid adoption of targeted oncology therapies. The United States anchors regional progress through extensive clinical trial activity, national guideline integration, and established laboratory-developed test and in vitro diagnostic ecosystems, while Canada benefits from public health technology assessment processes, provincial oncology programs, and expanding precision medicine initiatives.

Europe is shaped by the In Vitro Diagnostic Regulation, GDPR, national reimbursement systems, and strong translational research networks across Germany, France, Italy, Spain, and the United Kingdom. Asia-Pacific is expanding as China, Japan, South Korea, India, Australia, and ASEAN countries invest in cancer genomics, domestic diagnostic manufacturing, clinical trial capacity, and precision medicine access. Latin America is progressing through private-sector molecular diagnostics adoption and oncology modernization in Brazil and Mexico, while the Middle East is advancing through tertiary care centers, national genomics initiatives, and investment in advanced cancer care. Africa is developing more gradually, supported by regional reference laboratories, public health collaborations, and growing demand for molecular oncology diagnostics in major urban centers.

Key Group Insights Across Global Companion Diagnostics Markets

The European Union is a pivotal group for companion diagnostics because IVDR has increased requirements for clinical evidence, performance evaluation, and notified body oversight, pushing manufacturers toward more rigorous data packages and stronger post-market surveillance. G7 markets provide mature reimbursement frameworks, academic research depth, oncology guideline adoption, and drug development pipelines that support early CDx integration into therapeutic development, while NATO countries benefit from advanced healthcare infrastructure, secure data collaboration priorities, and cross-border clinical research networks.

BRICS countries are increasingly important because of large patient populations, expanding oncology treatment access, and government support for genomics and local diagnostic capacity, particularly in China, India, and Brazil, with Russia and South Africa contributing through regional laboratory infrastructure and evolving precision oncology programs. ASEAN markets are gaining relevance as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines expand laboratory networks and oncology services, though reimbursement and infrastructure remain uneven. GCC countries are investing in precision medicine, genomic screening, and advanced cancer centers, positioning the group as a high-potential environment for premium molecular diagnostics and oncology-linked CDx adoption.

Key Country Insights for Companion Diagnostics Adoption

The United States leads in companion diagnostics commercialization through FDA-approved CDx pathways, strong oncology guidelines, high biomedical R&D activity, and widespread use of NGS panels. Canada emphasizes evidence-based adoption through provincial health systems and health technology assessment, while Mexico and Brazil are expanding access through private oncology networks, reference laboratories, and growing demand for targeted therapies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced oncology care with national reimbursement decision-making, molecular tumor boards, and IVDR-aligned diagnostic standards, while Russia’s environment is shaped by local healthcare funding, domestic diagnostic capacity, and access considerations. China is scaling precision oncology through local innovation, hospital-based testing, and large clinical datasets; India is growing through cost-sensitive molecular testing and urban cancer centers; Japan and South Korea benefit from strong regulatory systems, high clinical adoption of advanced diagnostics, and precision oncology programs; and Australia supports adoption through public reimbursement mechanisms, national cancer genomics initiatives, and specialist pathology networks.

Actionable Recommendations for Companion Diagnostics Industry Leaders

Industry leaders should align CDx development with therapeutic development from the earliest clinical phases, ensuring biomarker strategy, assay design, sample logistics, and regulatory requirements are built into trial protocols. Co-development reduces approval risk and improves the probability that a diagnostic will be available when the therapy reaches clinical use.

Organizations should prioritize scalable NGS and liquid biopsy platforms, invest in real-world evidence, and build reimbursement dossiers that demonstrate clinical utility, analytical validity, and cost effectiveness. Strategic partnerships among drug developers, diagnostic manufacturers, reference laboratories, hospitals, academic centers, and digital health providers will be essential for faster turnaround time, equitable access, quality assurance, and broader precision medicine adoption.

Research Methodology for Companion Diagnostics Analysis

This executive summary is developed using a secondary research framework that synthesizes publicly available information from regulatory agencies, clinical guidelines, peer-reviewed biomedical literature, health technology assessment bodies, public health organizations, and recognized scientific sources. Key sources typically include the U.S. FDA, European Commission, national health agencies, WHO, IARC, oncology guideline bodies, and scientific publications covering molecular diagnostics, biomarker testing, and targeted therapy.

The methodology emphasizes triangulation across regulatory approvals, biomarker-linked therapy trends, diagnostic platform adoption, regional healthcare infrastructure, reimbursement dynamics, and technology developments. Insights are validated against observable signals such as CDx approvals, precision oncology programs, NGS utilization, AI governance developments, laboratory quality standards, and expanding clinical use of tissue and liquid biopsy testing.

Conclusion: Companion Diagnostics as a Precision Medicine Growth Engine

Companion diagnostics are no longer a specialized adjunct to drug development; they are a foundational component of precision medicine. As therapies become more biomarker-specific, the ability to deliver accurate, timely, and clinically validated diagnostic results will increasingly determine patient access, treatment selection, and healthcare value.

The sector’s evolution is supported by targeted therapy pipelines, expanding NGS adoption, liquid biopsy innovation, AI-enabled interpretation, and global investment in oncology infrastructure. Organizations that integrate regulatory excellence, evidence generation, reimbursement strategy, data governance, and laboratory scalability will be best positioned to lead the next phase of companion diagnostics advancement.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Companion Diagnostics Market, by Offering
7.1. Introduction
7.2. Instrumentation
7.2.1. Sample Preparation Systems
7.2.2. Amplification & Detection Instruments
7.2.3. Sequencers & Readers
7.3. Reagents & Consumables
7.3.1. Assay Reagent Kits
7.3.2. Primers Probes & Oligonucleotides
7.3.3. Antibodies & Staining Reagents
7.4. Software & Bioinformatics
7.4.1. Primary Data Processing
7.4.2. Variant Calling & Annotation
7.4.3. Clinical Interpretation & Reporting
7.5. Services
7.5.1. Assay Development & Validation
7.5.2. Clinical Trial Testing
7.5.3. Regulatory & Compliance Support
7.5.4. Data Analytics & Real-World Evidence Support
8. Companion Diagnostics Market, by Technology
8.1. Introduction
8.2. Immunoassay Technologies
8.2.1. Immunohistochemistry
8.2.2. ELISA
8.3. In Situ Hybridization
8.4. Next Generation Sequencing
8.4.1. Targeted Sequencing
8.4.2. Transcriptome Sequencing
8.4.3. Whole Genome Sequencing
8.5. Polymerase Chain Reaction (PCR)
8.5.1. Digital PCR
8.5.2. Real time PCR
8.6. Microarray Technologies
9. Companion Diagnostics Market, by Sample Type
9.1. Introduction
9.2. Tissue
9.3. Blood
9.4. Urine
9.5. Saliva
10. Companion Diagnostics Market, by Biomarker Class
10.1. Introduction
10.2. Molecular/Genomic Biomarkers
10.3. Protein Biomarkers
10.4. Pharmacogenetic Markers
10.5. Pharmacodynamic Markers
11. Companion Diagnostics Market, by Application
11.1. Introduction
11.2. Autoimmune & Inflammatory Diseases
11.3. Infectious Diseases
11.4. Oncology
11.4.1. Non-Small Cell Lung Cancer (NSCLC)
11.4.2. Breast Cancer
11.4.3. Colorectal Cancer
11.4.4. Melanoma
11.4.5. Hematologic Malignancies
11.5. Neurology
11.6. Endocrinology
12. Companion Diagnostics Market, by End User
12.1. Introduction
12.2. Academic & Research Organizations
12.3. Diagnostic Laboratories
12.4. Hospitals
12.5. Pharmaceutical & Biotechnology Companies
13. Companion Diagnostics Market, by Distribution Channel
13.1. Introduction
13.2. Direct Sales
13.3. Distributor Sales
13.4. Online Sales
14. Companion Diagnostics Market, by Region
14.1. North America
14.2. Asia-Pacific
14.3. Europe
14.4. Latin America
14.5. Middle East
14.6. Africa
15. Companion Diagnostics Market, by Group
15.1. NATO
15.2. G7
15.3. BRICS
15.4. European Union
15.5. GCC
15.6. ASEAN
16. Companion Diagnostics Market, by Country
16.1. United States
16.2. China
16.3. Canada
16.4. Germany
16.5. India
16.6. Mexico
16.7. Japan
16.8. United Kingdom
16.9. Brazil
16.10. France
16.11. Australia
16.12. Italy
16.13. Russia
16.14. South Korea
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. F. Hoffmann-La Roche AG
18.2. Abbott Laboratories
18.3. Danaher Corporation
18.4. Thermo Fisher Scientific Inc.
18.5. QIAGEN N.V.
18.6. Illumina, Inc.
18.7. Agilent Technologies, Inc.
18.8. Myriad Genetics, Inc.
18.9. Becton, Dickinson and Company
18.10. bioMérieux SA
18.11. Guardant Health, Inc
18.12. ARUP Laboratories
18.13. Caris Life Sciences
18.14. Almac Group Limited
18.15. Siemens Healthineers AG
18.16. Sanofi S.A.
18.17. Laboratory Corporation of America Holdings
18.18. Bio-Rad Laboratories, Inc.
18.19. Merck & Co., Inc.
18.20. Pfizer Inc.
18.21. Quest Diagnostics Incorporated
18.22. Abnova Corporation
18.23. Agendia, Inc.
18.24. Amoy Diagnostics Co., Ltd.
18.25. Bio-Techne Corporation
18.26. Eli Lilly and Company
18.27. ICON PLC
18.28. Invivoscribe, Inc.
18.29. NeoGenomics, Inc.
18.30. PathAI, Inc.
18.31. R-Biopharm AG
18.32. Sysmex Corporation
18.33. Tempus AI, Inc.
List of Figures
FIGURE 1. GLOBAL COMPANION DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL COMPANION DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL COMPANION DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL COMPANION DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
FIGURE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2025 VS 2032 (%)
FIGURE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL COMPANION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INSTRUMENTATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INSTRUMENTATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL SAMPLE PREPARATION SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL SAMPLE PREPARATION SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL SAMPLE PREPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL AMPLIFICATION & DETECTION INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL AMPLIFICATION & DETECTION INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL AMPLIFICATION & DETECTION INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SEQUENCERS & READERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SEQUENCERS & READERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SEQUENCERS & READERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ASSAY REAGENT KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ASSAY REAGENT KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ASSAY REAGENT KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PRIMERS PROBES & OLIGONUCLEOTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PRIMERS PROBES & OLIGONUCLEOTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PRIMERS PROBES & OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ANTIBODIES & STAINING REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIBODIES & STAINING REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIBODIES & STAINING REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SOFTWARE & BIOINFORMATICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SOFTWARE & BIOINFORMATICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SOFTWARE & BIOINFORMATICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PRIMARY DATA PROCESSING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PRIMARY DATA PROCESSING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PRIMARY DATA PROCESSING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL VARIANT CALLING & ANNOTATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL VARIANT CALLING & ANNOTATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL VARIANT CALLING & ANNOTATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CLINICAL INTERPRETATION & REPORTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CLINICAL INTERPRETATION & REPORTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CLINICAL INTERPRETATION & REPORTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ASSAY DEVELOPMENT & VALIDATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ASSAY DEVELOPMENT & VALIDATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ASSAY DEVELOPMENT & VALIDATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL CLINICAL TRIAL TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL CLINICAL TRIAL TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL CLINICAL TRIAL TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL REGULATORY & COMPLIANCE SUPPORT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL REGULATORY & COMPLIANCE SUPPORT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL REGULATORY & COMPLIANCE SUPPORT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL DATA ANALYTICS & REAL-WORLD EVIDENCE SUPPORT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL DATA ANALYTICS & REAL-WORLD EVIDENCE SUPPORT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL DATA ANALYTICS & REAL-WORLD EVIDENCE SUPPORT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL IMMUNOASSAY TECHNOLOGIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL IMMUNOASSAY TECHNOLOGIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL IMMUNOASSAY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ELISA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ELISA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL TRANSCRIPTOME SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL TRANSCRIPTOME SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL TRANSCRIPTOME SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL REAL TIME PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL REAL TIME PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL REAL TIME PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL MICROARRAY TECHNOLOGIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL MICROARRAY TECHNOLOGIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL MICROARRAY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL TISSUE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL TISSUE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL TISSUE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL URINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL URINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL SALIVA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL MOLECULAR/GENOMIC BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL MOLECULAR/GENOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL MOLECULAR/GENOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL PHARMACOGENETIC MARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL PHARMACOGENETIC MARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL PHARMACOGENETIC MARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL PHARMACODYNAMIC MARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL PHARMACODYNAMIC MARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL PHARMACODYNAMIC MARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL ACADEMIC & RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL ACADEMIC & RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL ACADEMIC & RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL DIRECT SALES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL DIRECT SALES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL DIRECT SALES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL DISTRIBUTOR SALES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL DISTRIBUTOR SALES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL DISTRIBUTOR SALES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL ONLINE SALES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL ONLINE SALES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL ONLINE SALES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 173. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 174. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 175. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 176. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 177. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2017-2032 (USD MILLION)
TABLE 178. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 179. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 180. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2017-2032 (USD MILLION)
TABLE 181. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 182. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2017-2032 (USD MILLION)
TABLE 183. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 184. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2017-2032 (USD MILLION)
TABLE 185. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 186. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 187. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 191. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 192. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 193. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2017-2032 (USD MILLION)
TABLE 194. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2017-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2017-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2017-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 206. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 207. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 208. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 209. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2017-2032 (USD MILLION)
TABLE 210. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 211. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 212. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2017-2032 (USD MILLION)
TABLE 213. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 214. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2017-2032 (USD MILLION)
TABLE 215. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 216. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2017-2032 (USD MILLION)
TABLE 217. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 218. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 219. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 220. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 222. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 223. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 224. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 225. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2017-2032 (USD MILLION)
TABLE 226. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 227. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 228. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2017-2032 (USD MILLION)
TABLE 229. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 230. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2017-2032 (USD MILLION)
TABLE 231. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 232. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2017-2032 (USD MILLION)
TABLE 233. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 234. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 235. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 237. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 238. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 239. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 240. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 241. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2017-2032 (USD MILLION)
TABLE 242. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 243. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 244. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2017-2032 (USD MILLION)
TABLE 245. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 246. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2017-2032 (USD MILLION)
TABLE 247. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 248. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2017-2032 (USD MILLION)
TABLE 249. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 250. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 251. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 253. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 254. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 255. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 256. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 257. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2017-2032 (USD MILLION)
TABLE 258. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 259. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 260. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2017-2032 (USD MILLION)
TABLE 261. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 262. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2017-2032 (USD MILLION)
TABLE 263. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 264. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2017-2032 (USD MILLION)
TABLE 265. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 266. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 267. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 269. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 270. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 271. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 272. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 273. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 274. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2017-2032 (USD MILLION)
TABLE 275. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 276. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 277. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2017-2032 (USD MILLION)
TABLE 278. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 279. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2017-2032 (USD MILLION)
TABLE 280. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 281. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2017-2032 (USD MILLION)
TABLE 282. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 283. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 284. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 285. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 286. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 287. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 288. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 289. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 290. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2017-2032 (USD MILLION)
TABLE 291. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 292. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 293. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2017-2032 (USD MILLION)
TABLE 294. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 295. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2017-2032 (USD MILLION)
TABLE 296. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 297. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2017-2032 (USD MILLION)
TABLE 298. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 299. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 300. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 301. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 302. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 303. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 304. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 305. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 306. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2017-2032 (USD MILLION)
TABLE 307. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 308. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 309. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2017-2032 (USD MILLION)
TABLE 310. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 311. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2017-2032 (USD MILLION)
TABLE 312. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 313. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2017-2032 (USD MILLION)
TABLE 314. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 315. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 316. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 317. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 318. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 319. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 320. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 321. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 322. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2017-2032 (USD MILLION)
TABLE 323. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 324. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 325. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2017-2032 (USD MILLION)
TABLE 326. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 327. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2017-2032 (USD MILLION)
TABLE 328. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 329. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2017-2032 (USD MILLION)
TABLE 330. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 331. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 332. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 333. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 334. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 335. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 336. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTATION, 2017-2032 (USD MILLION)
TABLE 337. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 338. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2017-2032 (USD MILLION)
TABLE 339. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 340. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 341. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY TECHNOLOGIES, 2017-2032 (USD MILLION)
TABLE 342. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 343. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2017-2032 (USD MILLION)
TABLE 344. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 345. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY BIOMARKER CLASS, 2017-2032 (USD MILLION)
TABLE 346. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 347. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 348. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 349. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 350. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 351. ASEAN COMPANION DIAGNOSTICS MARKET SIZE,

Companies Mentioned

  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Myriad Genetics, Inc.
  • Becton, Dickinson and Company
  • bioMérieux SA
  • Guardant Health, Inc
  • ARUP Laboratories
  • Caris Life Sciences
  • Almac Group Limited
  • Siemens Healthineers AG
  • Sanofi S.A.
  • Laboratory Corporation of America Holdings
  • Bio-Rad Laboratories, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Quest Diagnostics Incorporated
  • Abnova Corporation
  • Agendia, Inc.
  • Amoy Diagnostics Co., Ltd.
  • Bio-Techne Corporation
  • Eli Lilly and Company
  • ICON PLC
  • Invivoscribe, Inc.
  • NeoGenomics, Inc.
  • PathAI, Inc.
  • R-Biopharm AG
  • Sysmex Corporation
  • Tempus AI, Inc.

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 9.84 Billion
Forecasted Market Value ( USD ) by 2032 $ 18.48 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

Biomarker Testing Services Market - Global Forecast 2026-2032 - Product Image

Biomarker Testing Services Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Biomarkers Market - Global Forecast 2026-2032 - Product Image

Biomarkers Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Cancer Biomarkers Market - Types, Applications and Technologies - Product Image

Cancer Biomarkers Market - Types, Applications and Technologies

  • Report
  • 326 Pages
  • Global
From
Biomarker Testing Services - Global Strategic Business Report - Product Image

Biomarker Testing Services - Global Strategic Business Report

  • Report
  • 152 Pages
  • Global
From
Global Cancer Biomarker Market - Strategic Insights and Forecasts (2026-2031) - Product Image

Global Cancer Biomarker Market - Strategic Insights and Forecasts (2026-2031)

  • Report
  • 146 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.